Vaccine Development
MVA85A
Clinical IIb | Boost | Oxford-Emergent Tuberculosis Consortium
News and Publications Aeras News
> 2.03.2013 Statement by Tom Evans, MD, Interim CEO:
First TB Vaccine Efficacy Study in Almost a Century Provides Key Insights
> 2.03.2013 Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine Candidate MVA85A Published in The Lancet
> 8.10.2011 New Tuberculosis Vaccine Enters Phase IIb Proof-of-Concept Trial in People Living with HIV in Senegal and South Africa
> 4.27.2011 Enrollment Complete for Proof-of-Concept Study of a New TB Vaccine in South Africa
> 7.23.2008 Aeras to Support Promising TB Vaccine Candidate - AERAS-485/Oxford MVA85A
On the web
> The University of Oxford's Medical Sciences Division > Emergent BioSolutions Inc. > Isis Innovation Ltd > Wellcome Trust
Scientific Publications
> THE LANCET | 2.4.2013 Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial > VACCINE | 2.4.2013
Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery > AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 1.26.2012
A phase IIa Trial of the new TB Vaccine, MVA85A, in HIV and/or M. Tuberculosis Infected Adults. > THE JOURNAL OF INFECTIOUS DISEASES | 6.15.2012
Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. > SCIENCE TRANSLATIONAL MEDICINE | 6.22.2011
Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants > JOURNAL OF INFECTIOUS DISEASES | 2011
Dose-Finding Study of the Novel Tuberculosis Vaccine, MVA85A, in Healthy BCG-Vaccinated Infants > CLINICAL AND VACCINE IMMUNOLOGY | 5.19.2010
Investigating the Induction of Vaccine-Induced Th17 and Regulatory T Cells in Healthy, Mycobacterium bovis BCG-Immunized Adults Vaccinated with a New Tuberculosis Vaccine, MVA85A > PLOS ONE | 8.26.2011
Th1/Th17 Cell Induction and Corresponding Reduction in ATP Consumption following Vaccination with the Novel Mycobacterium tuberculosis Vaccine MVA85A > EUROPEAN JOURNAL OF IMMUNOLOGY | 2010
MVA85A, a novel TB vaccine, is safe in adolescents and children, and induces complex subsets of polyfunctional CD4+ T cells > INFECTION AND IMMUNITY | 2005
Boosting with Poxviruses Enhances Mycobacterium bovis BCG Efficacy against Tuberculosis in Guinea Pigs > EUROPEAN JOURNAL OF IMMUNOLOGY | 2007
Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations > PLOS ONE | 8.13.2008
Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa > VACCINE | 9.26.2008
Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-1 > JOURNAL OF IMMUNOLOGY | 8.1.2003
Enhanced Immunogenicity and Protective Efficacy Against Mycobacterium tuberculosis of Bacille Calmette-Gue´rin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara1 > JOURNAL OF INFECTIOUS DISEASES | 8.15.2008
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa > NATURE MEDICINE | 10.24.2004
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimicrobial immunity in humans > PLOS ONE | 10.24.2007
Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials > AMERICAN JOURNAL OF CRITICAL CARE AND RESPIRATORY MEDICINE | 4.15.2009
Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals > PLOS ONE | 12.23.2008
Safety and Immunogenciity of Booting BCG Vaccinated Subjects with BCG; Comparison with Boosting with a New TB Vaccine, MVA85A > EUROPEAN JOURNAL OF IMMUNOLOGY | 12.16.2009
Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells > VACCINE | 6.27.2012
A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants > THE LANCET | 2.04.2013
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
News and Publications Aeras News
> 2.03.2013 Statement by Tom Evans, MD, Interim CEO:
First TB Vaccine Efficacy Study in Almost a Century Provides Key Insights
> 2.03.2013 Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine Candidate MVA85A Published in The Lancet
> 8.10.2011 New Tuberculosis Vaccine Enters Phase IIb Proof-of-Concept Trial in People Living with HIV in Senegal and South Africa
> 4.27.2011 Enrollment Complete for Proof-of-Concept Study of a New TB Vaccine in South Africa
> 7.23.2008 Aeras to Support Promising TB Vaccine Candidate - AERAS-485/Oxford MVA85A
On the web
> The University of Oxford's Medical Sciences Division > Emergent BioSolutions Inc. > Isis Innovation Ltd > Wellcome Trust
Scientific Publications
> THE LANCET | 2.4.2013 Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial > VACCINE | 2.4.2013
Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery > AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 1.26.2012
A phase IIa Trial of the new TB Vaccine, MVA85A, in HIV and/or M. Tuberculosis Infected Adults. > THE JOURNAL OF INFECTIOUS DISEASES | 6.15.2012
Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. > SCIENCE TRANSLATIONAL MEDICINE | 6.22.2011
Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants > JOURNAL OF INFECTIOUS DISEASES | 2011
Dose-Finding Study of the Novel Tuberculosis Vaccine, MVA85A, in Healthy BCG-Vaccinated Infants > CLINICAL AND VACCINE IMMUNOLOGY | 5.19.2010
Investigating the Induction of Vaccine-Induced Th17 and Regulatory T Cells in Healthy, Mycobacterium bovis BCG-Immunized Adults Vaccinated with a New Tuberculosis Vaccine, MVA85A > PLOS ONE | 8.26.2011
Th1/Th17 Cell Induction and Corresponding Reduction in ATP Consumption following Vaccination with the Novel Mycobacterium tuberculosis Vaccine MVA85A > EUROPEAN JOURNAL OF IMMUNOLOGY | 2010
MVA85A, a novel TB vaccine, is safe in adolescents and children, and induces complex subsets of polyfunctional CD4+ T cells > INFECTION AND IMMUNITY | 2005
Boosting with Poxviruses Enhances Mycobacterium bovis BCG Efficacy against Tuberculosis in Guinea Pigs > EUROPEAN JOURNAL OF IMMUNOLOGY | 2007
Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations > PLOS ONE | 8.13.2008
Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa > VACCINE | 9.26.2008
Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-1 > JOURNAL OF IMMUNOLOGY | 8.1.2003
Enhanced Immunogenicity and Protective Efficacy Against Mycobacterium tuberculosis of Bacille Calmette-Gue´rin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara1 > JOURNAL OF INFECTIOUS DISEASES | 8.15.2008
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa > NATURE MEDICINE | 10.24.2004
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimicrobial immunity in humans > PLOS ONE | 10.24.2007
Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials > AMERICAN JOURNAL OF CRITICAL CARE AND RESPIRATORY MEDICINE | 4.15.2009
Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals > PLOS ONE | 12.23.2008
Safety and Immunogenciity of Booting BCG Vaccinated Subjects with BCG; Comparison with Boosting with a New TB Vaccine, MVA85A > EUROPEAN JOURNAL OF IMMUNOLOGY | 12.16.2009
Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells > VACCINE | 6.27.2012
A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants > THE LANCET | 2.04.2013
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
Donate to Aeras via